Влияние терапии ингибиторами фактора некроза опухоли α на трудоспособность больных анкилозирующим спондилитом
https://doi.org/10.14412/1996-7012-2016-1-63-66
Аннотация
Об авторах
Ш. Ф. ЭрдесРоссия
115522, Москва, Каширское шоссе, 34А
М. В. Подряднова
Россия
115522, Москва, Каширское шоссе, 34А
Литература
1. Chorus AM, Miedema HS, Boonen A, Van Der Linden S. Quality of life and work in patients with rheumatoid arthritis and ankylosing spondylitis of working age. Ann Rheum Dis. 2003 Dec;62(12):1178-84.
2. Подряднова МВ, Балабанова РМ, Урумова ММ, Эрдес ШФ. Взаимосвязь клинических характеристик анкилозирующего спондилита с трудоспособностью и производительностью труда. Научно-практическая ревматология. 2014;52(5):513–9. [Podryadnova MV, Balabanova RM, Urumova MM, Erdes ShF. Correlation between clinical characteristics of ankylosing spondylitis and work capacity and productivity. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(5):513–9. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2014-513-519
3. Cakar E, Taskaynatan MA, Dincer U, et al. Work disability in ankylosing spondylitis: differences among working and work-disabled patients. Clin Rheumatol. 2009 Nov;28(11):1309-14. doi: 10.1007/s10067-009-1249-1. Epub 2009 Aug 16.
4. Brunner R, Kissling RO, Auckenthaler C, Fortin J. Clinical evaluation of ankylosing spondylitis in Switzerland. Pain Physician. 2002 Jan;5(1):49-56.
5. Фоломеева ОМ, Лобарева ЛС, Ушакова МА. Инвалидность, обусловленная ревматическими заболеваниями, среди жителей Российской Федерации. Научно-практическая ревматология. 2001;39(1):15–21. [Folomeeva OM, Lobareva LS, Ushakova MA. Disability caused by rheumatic diseases among residents of the Russian Federation. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2001;39(1):15–21. (In Russ.)].
6. Gran JT, Scomsvoll JF. The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol. 1997 Jul;36(7): 766-71.
7. Boonen A, van der Heijde D. Review of the costs of illness of ankylosing spondylitis and methodologic notes. Expert Rev Pharmacoecon Outcomes Res. 2005 Apr;5(2):163-81. doi: 10.1586/14737167.5.2.163.
8. Listing J, Brandt J, Rudwaleit M, et al. Impact of anti-tumour necrosis factor alpha treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis. Ann Rheum Dis. 2004 Dec;63(12):1670-2.
9. Haibel Н, Song IH, Rudwaleit M, et al. Multicenter open-label study with infliximab in active ankylosing spondylitis over 28 weeks in daily practice. Clin Exp Rheumatol. 2008 Mar-Apr;26(2):247-52.
10. Han С, Kavanaugh А, Genovese МС, et al. Sustained Improvement in Health Related Quality of Life, Work Productivity, Employability, and Reduced Healthcare Resource Utilization of Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Treated with Golimumab: 5yr Results. Ann Rheum. 2013;72:A337 doi:10.1136/annrheumdis-2013-eular.1041
11. van der Burg LRA, ter Wee MM, Boonen A. Effect of biological therapy on work participation in patients with ankylosing spondylitis: a systematic review. Ann Rheum Dis. 2012 Dec;71(12):1924-33. doi: 10.1136/annrheumdis-2012-201914. Epub 2012 Sep 6.
12. Maksymowych WP, Curtis S, Dougados M, et al. Quality of life in Patients with Active Nonradiographic Axial Spondyloarthritis After 16 Weeks of Golimumab Treatment. Ann Rheum Dis. 2015;74:1151-1152 doi:10.1136/annrheumdis-2015-eular.3046
13. Thomas M, Kruger K, Aries P, et al. Nicht interventionelle Evaluierung: Klinisches Bild, ArbeitsfКhigkeit und LebensqualitКt unter Golimumab – 2. Interimsanalyse GO-NICE Kongress der DGRh, Dü sseldorf, Germany 17-20 Sep 2014 Abst .143, Poster RA.18.
14. Tubery A, Castelli C, Erny F, et al. The effect of biological agents on work in patients with chronic inflammatory arthritides: a meta-analysis of randomized controlled trials and controlled cohorts. Ann Rheum Dis. 2015;74(Suppl2):124. DOI: 10.1136/annrheumdis-2015-eular.4799
15. Deodhar A, Mittal M, Joshi A, et al. Assessment of salary growth in patients with ankylosing spondylitis treated with and without anti-tumor necrosis factor therapy. Ann Rheum Dis. 2015;74(Suppl2): 744. DOI: 10.1136/annrheumdis-2015-eular.3663
Рецензия
Для цитирования:
Эрдес ШФ, Подряднова МВ. Влияние терапии ингибиторами фактора некроза опухоли α на трудоспособность больных анкилозирующим спондилитом. Современная ревматология. 2016;10(1):63-66. https://doi.org/10.14412/1996-7012-2016-1-63-66
For citation:
Erdes SF, Podryadnova MV. Impact of therapy with tumor necrosis factor-α inhibitors on the working ability of patients with ankylosing spondylitis. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2016;10(1):63-66. (In Russ.) https://doi.org/10.14412/1996-7012-2016-1-63-66